Suscribirse

Severe COVID-19 pneumonia: clinical, functional, and imaging outcomes at 4 months - 28/04/21

Doi : 10.1016/j.resmer.2021.100822 
Elise Noel-Savina 1, , Thibault Viatgé 1, Guillaume Faviez 1, Benoît Lepage 2, Laurent Mhanna 1, Sandrine Pontier 1, Marion Dupuis 1, Samia Collot 3, Pascal. Thomas 4, Jon Idoate Lacasia 1, Laure Crognier 5, Sihem Bouharaoua 5, Stein Silva Sifontes 4, Julien Mazières 1, Grégoire Prévot 1, Alain Didier 1
1 Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France 
2 Department of Epidemiology, CHU Toulouse, Toulouse, France 
3 Department of Medical Imaging, Rangueil Hospital, CHU Toulouse, Toulouse, France 
4 Department of Nuclear Medicine, Rangueil Hospital, CHU Toulouse, Toulouse, France 
5 Adult Intensive Care Unit, CHU Toulouse, Toulouse, France 

Correspondence: Department of Pneumology and respiratory intensive care unit, Toulouse University Hospital, Larrey Hospital, Chemin de Pouvourville, 31400 Toulouse, FranceDepartment of Pneumology and respiratory intensive care unit, Toulouse University Hospital, Larrey Hospital, Chemin de PouvourvilleToulouse31400France

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

En prensa. Manuscrito Aceptado. Disponible en línea desde el Wednesday 28 April 2021
This article has been published in an issue click here to access

ABSTRACT

Introduction: Given the pathophysiology of coronavirus disease 19 (COVID-19), persistent pulmonary abnormalities are likely.

Methods:We conducted a prospective cohort study in severe COVID-19 patients who had oxygen saturation <94% and were primarily admitted to hospital. We aimed to describe persistent gas exchange abnormalities at 4 months, defined as decreased diffusing capacity of the lungs for carbon monoxide (DLco) and/or desaturation on the 6-minute walk test (6MWT), along with associated mechanisms and risk factors

Results: Of the 72 patients included, 76.1% required admission to the intensive care unit (ICU), while 68.5% required invasive mechanical ventilation (MV). 39.1% developed venous thromboembolism (VTE). At 4 months, 61.4% were still symptomatic. Functionally, 39.1% had abnormal carbon monoxide test results and/or desaturation on 6MWT; high-flow oxygen, MV, and VTE during the acute phase were significantly associated. Restrictive lung disease was observed in 23.6% of cases, obstructive lung disease in 16.7%, and respiratory muscle dysfunction in 18.1%. A severe initial presentation with admission to ICU (p=.0181), and VTE occurrence during the acute phase (p=.0089) were associated with these abnormalities. 41% had interstitial lung disease in computed tomography (CT) of the chest. Four patients (5.5%) displayed residual defects on lung scintigraphy, only one of whom had developed VTE during the acute phase (5.5%). The main functional respiratory abnormality (31.9%) was reduced capillary volume (Vc<70%).

Conclusion: Among patients with severe COVID-19 pneumonia who were admitted to hospital, 61% were still symptomatic, 39% of patients had persistent functional abnormalities and 41% radiological abnormalities after 4 months. Embolic sequelae were rare but the main functional respiratory abnormality was reduced capillary volume. A respiratory check-up after severe COVID-19 pneumonia may be relevant to improve future management of these patients.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, follow-up, sequelae: pulmonary embolism, fibrosis



© 2021  SPLF and Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.